Prognosis
AstraZeneca Pressure Mounts as Investors Await Oxford Vaccine Data
- Early-stage vaccine trial data set to be published Monday
- Oxford-Astra shot is a frontrunner in race for vaccine
This article is for subscribers only.
Pressure is growing on AstraZeneca Plc to deliver positive results from early tests evaluating the coronavirus vaccine it’s developing with University of Oxford researchers as investors await data expected on Monday.
The U.K. pharma company is staying quiet after British media reports said results of phase 1 tests to be published in The Lancet medical journal were promising, driving the shares up late Wednesday. A paper is undergoing final editing and preparation and is due to be published on July 20, The Lancet said in an email. The trial started in April and saw more than 1,000 shots tested on healthy adult volunteers.